Akoya Biosciences $50 million at-the-market program
The common stock is listed on the Nasdaq Global Select Market
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market program by Akoya Biosciences, Inc. of shares of its common stock for up to a maximum offering price of $50 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “AKYA.”
Akoya Biosciences offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression, treatment response, and that empower clinicians to improve patient outcomes. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. With these platforms, Akoya’s customers are performing spatial phenotyping to further advance their understanding and treatment of diseases such as cancer, neurological and autoimmune disorders and many other therapeutic areas.
The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associate Meaghan Kennedy. Partner David R. Bauer and associate David A. Frey provided intellectual property advice. The tax team included counsel Christopher A. Baratta and associate Yueyu Yang. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.